SCHEDULE 13G 0001633313 XXXXXXXX LIVE Ordinary Shares, par value EUR0.05 per share 06/30/2025 0001590560 uniQure N.V. N90064101 PAASHEUVELWEG 25A AMSTERDAM P7 1105 BP Rule 13d-1(b) Avoro Capital Advisors LLC b DE 3625000.00 0.00 3625000.00 0.00 3625000.00 N 6.6 IA OO Behzad Aghazadeh b X1 3625000.00 0.00 3625000.00 0.00 3625000.00 N 6.6 HC IN uniQure N.V. Paasheuvelweg 25a, 1105 BP Amsterdam, The Netherlands This statement is filed by: (i) Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro"), which provides investment advisory and management services and has acquired the ordinary shares, par value EUR0.05 per share ("Ordinary Shares") of uniQure N.V., a public limited liability company incorporated under the laws of the Netherlands (the "Issuer"), solely for investment purposes on behalf of Avoro Life Sciences Fund LLC, a Delaware limited liability company, and (ii) Behzad Aghazadeh ("Dr. Aghazadeh," and together with Avoro, the "Reporting Persons"), who serves as the portfolio manager and controlling person of Avoro. The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein. The address of the business office of each of the Reporting Persons is 110 Greene Street, Suite 800, New York, NY 10012. Avoro is a Delaware limited liability company. Dr. Aghazadeh is a United States citizen. N IA HC The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon 54,748,496 Ordinary Shares outstanding as of May 6, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the Securities and Exchange Commission on May 9, 2025. 6.6% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Y N See Item 2(a). Avoro Life Sciences Fund LLC has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the Ordinary Shares. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1: Joint Filing Agreement Avoro Capital Advisors LLC /s/ Scott Epstein 08/14/2025 Behzad Aghazadeh /s/ Behzad Aghazadeh 08/14/2025